Compositions and methods for treating skin cancer associated diseases
View Patent ↗The invention provides compositions and methods for treating skin cancer associated diseases. Specifically, the invention relates to topically administering a signaling pathway inhibitor or a related compound to treat pre-cancerous skin lesions, skin tumors, and their associated diseases or disorders.
1. A method for treating a skin cancer related disease or disorder in a subject, the method comprising: topically administering to said subject a therapeutically effective amount of a PI3K/PDK1/AKT signaling pathway tyrosine kinase inhibitor, wherein the disease or disorder is actinic keratosis, a squamous cell carcinoma in situ like lesion, or a cutaneous squamous cell carcinoma.
2. The method of claim 1 , wherein said disease or disorder is actinic keratosis.
3. The method of claim 1 , wherein said disease or disorder is a squamous cell carcinoma in situ like lesion.
4. The method of claim 1 , wherein said disease or disorder is associated with cutaneous squamous cell carcinoma.
5. The method of claim 1 , wherein said inhibitor is administered in combination with at least one other treatment regime selected from the group consisting of chemotherapy, immunotherapy, radiation therapy, photodynamic therapy, electrocautery, laser therapy, and surgery.
6. The method of claim 1 , wherein said subject is a human.
7. The method of claim 1 , wherein said inhibitor has a molecular weight of less than 500 daltons.
8. A method for treating a skin cancer related disease or disorder in a subject having said disease or disorder, the method comprising: topically administering to said subject a therapeutically effective amount of a MAPK/ERK signaling pathway tyrosine kinase inhibitor, wherein the disease or disorder is actinic keratosis, a squamous cell carcinoma in situ like lesion, or a cutaneous squamous cell carcinoma.
9. The method of claim 8 , wherein said disease or disorder is actinic keratosis.
10. The method of claim 8 , wherein said disease or disorder is a squamous cell carcinoma in situ like lesion.
11. The method of claim 8 , wherein said disease or disorder is associated with cutaneous squamous cell carcinoma.
12. The method of claim 8 , wherein said inhibitor is administered in combination with at least one other treatment regime selected from the group consisting of chemotherapy, immunotherapy, radiation therapy, photodynamic therapy, electrocautery, laser therapy, and surgery.
13. The method of claim 8 , wherein said subject is a human.
14. The method of claim 8 , wherein said inhibitor has a molecular weight of less than 500 daltons.
15. A method for treating a skin cancer related disease or disorder in a subject, the method comprising: topically administering to said subject a therapeutically effective amount of a JAK-STAT signaling pathway tyrosine kinase inhibitor, wherein the disease or disorder is actinic keratosis, a squamous cell carcinoma in situ like lesion, or a cutaneous squamous cell carcinoma.
16. The method of claim 15 , wherein said disease or disorder is actinic keratosis.
17. The method of claim 15 , wherein said disease or disorder is a squamous cell carcinoma in situ like lesion.
18. The method of claim 15 , wherein said disease or disorder is associated with cutaneous squamous cell carcinoma.
19. The method of claim 15 , wherein said inhibitor is administered in combination with at least one other treatment regime selected from the group consisting of chemotherapy, immunotherapy, radiation therapy, photodynamic therapy, electrocautery, laser therapy, and surgery.
20. The method of claim 15 , wherein said subject is a human.
21. The method of claim 15 , wherein said inhibitor has a molecular weight of less than 500 daltons.
22. A method for treating a skin cancer related disease or disorder in a subject, the method comprising: topically administering to said subject a therapeutically effective amount of a compound, wherein the compound is a tyrosine kinase inhibitor and inhibits both PI3K and mTOR.
23. A method for treating a skin cancer related disease or disorder in a subject, the method comprising: topically administering to said subject a therapeutically effective amount of CEP-11981.
24. The method of claim 23 , wherein said disease or disorder is actinic keratosis.
25. The method of claim 23 , wherein said disease or disorder is a squamous cell carcinoma in situ like lesion.
26. The method of claim 23 , wherein said disease or disorder is associated with cutaneous squamous cell carcinoma.
27. The method of claim 23 , wherein said inhibitor is administered in combination with at least one other treatment regime selected from the group consisting of chemotherapy, immunotherapy, radiation therapy, photodynamic therapy, electrocautery, laser therapy, and surgery.
28. The method of claim 23 , wherein said subject is human.
29. The method of claim 23 , wherein said inhibitor has a molecular weight of less than 500 daltons.
30. The method of claim 23 , wherein the compound is BEZ235.
31. The method of claim 24 , wherein said disease or disorder is actinic keratosis.
32. The method of claim 24 , wherein said disease or disorder is a squamous cell carcinoma in situ like lesion.
33. The method of claim 24 , wherein said disease or disorder is associated with cutaneous squamous cell carcinoma.
34. The method of claim 24 , wherein said inhibitor is administered in combination with at least one other treatment regime selected from the group consisting of chemotherapy, immunotherapy, radiation therapy, photodynamic therapy, electrocautery, laser therapy, and surgery.
35. The method of claim 24 , wherein said subject is human.